(Q37780221)

23 August 2017

1 reference

title

Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit (English)

1 reference

23 August 2017

main subject

coronary artery disease

1 reference

2

Eric Boersma

1 reference

23 August 2017

3

Maarten L Simoons

1 reference

23 August 2017

Jasper J Brugts

1

1 reference

23 August 2017

publication date

1 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

11

1 reference

23 August 2017

issue

8

1 reference

23 August 2017

page(s)

1115-1126

1 reference

Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Pat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Secondary prevention of coronary disease with ACE inhibition--does blood pressure reduction with perindopril explain the benefits in EUROPA?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Gene-load score of the renin–angiotensin–aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

Aneurysm formation and bradykinin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.103

21 January 2018

Identifiers

DOI

10.2217/PGS.10.103

1 reference

23 August 2017

1 reference